Last reviewed · How we verify
NCT05536570
Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.
Phase 4 trial testing IncobotulinumtoxinA 100 UNT in Thoracic Outlet Syndrome in 15 participants. Status unknown.
15 April 2023
Quick facts
| Lead sponsor | King, David, MD |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 15 October 2022 |
| Primary completion | 15 April 2023 |
| Estimated completion | 15 June 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- IncobotulinumtoxinA 100 UNT — full drug profile →
Conditions studied
- Thoracic Outlet Syndrome — all drugs for Thoracic Outlet Syndrome →
- Whiplash Injuries — all drugs for Whiplash Injuries →
Sponsor
King, David, MD
Who can join
Eligibility, any sex, with Thoracic Outlet Syndrome or Whiplash Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Whiplash injuries following car accident are common, it has been reported to affect 83% of individuals injured in traffic collisions (Yadla S, 2007). The condition is caused by a rapid acceleration followed immediately by a rapid deceleration of the neck and head. The annual North American incidence rate is estimated to be 600 per 100,000 people (Holm LW, 2008). The condition is costly for society and disabling/painful for the patients. Depending on the collision type, the biomechanics of muscles will be affected differently and consequently the clinical presentation will vary. T-bone type of car collisions (when the front of one vehicle strikes the side of another) may induce thoracic outlet syndrome (TOS) following compression on the nerve and artery bundle by the scalene muscles (lateral stabilizers of the neck). An appropriate and detailed examination of the patient is necessary to identify the cause of the resulting pain and disability. Once a functional thoracic outlet syndrome is identified the proposal is to treat this with botulinum toxin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05536570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IncobotulinumtoxinA 100 UNT
Trials testing the same drug.
- NCT06250543 — Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder · Phase 4 · completed
Other recruiting trials for Thoracic Outlet Syndrome
Currently open trials in the same condition.
- NCT06992752 — Dysfunctional Breathing in Individuals With Thoracic Outlet Syndrome · recruiting
- NCT06095700 — First Rib Resection Versus Avulsion for Thoracic Outlet Syndrome · NA · recruiting
- NCT05628948 — Vascular Lab Resource (VLR) Biorepository · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05536570 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King, David, MD
- Last refreshed: 13 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05536570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing